Compare · NVS vs VNDA
NVS vs VNDA
Side-by-side comparison of Novartis AG (NVS) and Vanda Pharmaceuticals Inc. (VNDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and VNDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $279.39B, about 782.2x VNDA ($357.2M).
- Over the past year, NVS is up 24.1% and VNDA is up 29.6% - VNDA leads by 5.4 points.
- VNDA has hit the wire 12 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 5 for VNDA).
- Company
- Novartis AG
- Vanda Pharmaceuticals Inc.
- Price
- $146.50-1.72%
- $5.94-1.41%
- Market cap
- $279.39B
- $357.2M
- 1M return
- +0.71%
- -6.97%
- 1Y return
- +24.12%
- +29.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2006
- News (4w)
- 0
- 12
- Recent ratings
- 25
- 5
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG
Latest VNDA
- SVP, GC and Secretary Mcguire Daniel Patrick was granted 80,000 shares, increasing direct ownership by 267% to 109,982 units (SEC Form 4)
- Director Chrousos Phaedra was granted 41,600 shares, increasing direct ownership by 34% to 164,950 units (SEC Form 4)
- Director Duncan Charles Cliff was granted 41,600 shares, increasing direct ownership by 73% to 98,701 units (SEC Form 4)
- Director Dugan Richard W was granted 41,600 shares, increasing direct ownership by 23% to 219,054 units (SEC Form 4)
- Director Ward Anne Sempowski was granted 41,600 shares, increasing direct ownership by 35% to 160,667 units (SEC Form 4)
- Director Honore Tage was granted 41,600 shares, increasing direct ownership by 45% to 135,069 units (SEC Form 4)
- Director Mitchell Stephen Ray was granted 41,600 shares, increasing direct ownership by 58% to 112,846 units (SEC Form 4)
- New insider Mcguire Daniel Patrick claimed ownership of 29,982 shares (SEC Form 3)
- SEC Form S-8 filed by Vanda Pharmaceuticals Inc.
- Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders